Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
1821-12-1
Molecular formula
C10H12O2
Molecular weight
164.2 g/mol
Drug class
Ammonia-scavenging nitrogen-binding agenttreatment for urea-cycle disorders
Mechanism of action
Phenylbutyrate is metabolised to phenylacetate, which conjugates with glutamine to form phenylacetylglutamine. This nitrogen-containing conjugate is excreted in urine, providing an alternative pathway for waste-nitrogen removal and lowering plasma ammonia.
Indications / reported uses
Adjunctive chronic management of patients with urea-cycle disorders involving deficiencies of carbamoyl phosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase, in conjunction with dietary management and other indicated therapy.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Phenylbutyrate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Phenylbutyrate Permitted Daily Exposure (PDE) report (the Phenylbutyrate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Phenylbutyrate Occupational Exposure Limit (OEL) report (the Phenylbutyrate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.